Global market for Cholesterol Testing is projected to reach 2.9 billion tests by 2020
Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Cholesterol Testing markets. Global market for Cholesterol Testing is projected to reach 2.9 billion tests by 2020, driven by the surge in health conditions such as diabetes, obesity and hypertension.
Cholesterol tests generally measure the level of each type of cholesterol carrier or lipoprotein in the blood. Such tests are essential since the presence of excessive cholesterol levels in the body, especially along the walls of blood vessels, is a precursor condition to heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading cause of fatality worldwide, therefore testing for cholesterol levels on a regular basis, to assess an individual’s risk profile for CVD is essential. Other factors entailing regular cholesterol testing include family history of heart disease; individuals with high blood pressure, diabetes, and obesity; all regarded to be high risk factors. Tests for cholesterol include Complete Lipid Profile / Lipid Panel Test (providing Total Cholesterol, LDL cholesterol, HDL cholesterol, and Triglycerides levels); Apolipoprotein B Test; Apolipoprotein A1 and other tests. Growth in the cholesterol testing market is encouraged by growing awareness over the importance of testing as a measure to reduce fatality and improve diagnosis and treatment of CVD.
Other key factors driving growth in the market include improved understanding of CVD, development of biomarkers to effectively identify the risk of the condition, and increase in healthcare spending. Rising preference for CVD risk assessment owing to reduced insurance coverage and increasing out-of-pocket expenses associated with therapeutic treatments, is additionally promoting preventive healthcare practices. A vast majority of population remains undiagnosed thus promising significant opportunities for growth of testing volumes. New guidelines, publications, and awareness programs will additionally boost testing volumes. Rising preference for healthy lifestyles and improved quality of life among individuals is a key factor driving demand for cholesterol and other cardiovascular risk assessment tests.
Lipid Panel Test/Complete Lipid Profile is the most prevalent and widely recommended cholesterol test type globally. However, new variants of cardiovascular and other tests such as homocysteine test, C-reactive protein test are growing in popularity, promising more accuracy in CVD risk assessment. Technological advancements resulting in miniaturization of devices is expected to play a crucial role in driving demand for cholesterol self-test kits. Increasing preference for home testing and subsequent rise in demand for OTC cholesterol test kits is a key trend in the market.
As stated by the new market research report on Cholesterol Testing, Asia-Pacific ranks as the fastest growing market worldwide. Favorable demographical factors such as the rising population, better access to affordable healthcare, changing lifestyles and the subsequent rise in risk of cardiovascular diseases, are major factors promoting growth in the region. China is forecast to grow at a CAGR of 7.5% over the analysis period, led by rising disposable income, growing health consciousness, aging population, and growing awareness over available cholesterol testing solutions. The United States represents the largest market with cardiovascular diseases accounting for a major portion of dollars spent on chronic diseases in the country.
Key players covered in the report include Abbott Diagnostics Inc., AccuTech LLC, Alere Inc., Beckman Coulter Inc., Chek Diagnostics, F. Hoffmann-La Roche Ltd., Home Access Health Corporation, and Siemens Healthcare, among others.
The research report titled "Cholesterol Testing: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in dollars for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World. Test Types analyzed in the report include Lipid Panel Test/Complete Lipid Profile, Apolipoprotein B Test, and Other Cholesterol Tests.
GIA announces the release of a comprehensive global report on Cholesterol Testing markets. Global market for Cholesterol Testing is projected to reach 2.9 billion tests by 2020, driven by the surge in health conditions such as diabetes, obesity and hypertension.
Cholesterol tests generally measure the level of each type of cholesterol carrier or lipoprotein in the blood. Such tests are essential since the presence of excessive cholesterol levels in the body, especially along the walls of blood vessels, is a precursor condition to heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading cause of fatality worldwide, therefore testing for cholesterol levels on a regular basis, to assess an individual’s risk profile for CVD is essential. Other factors entailing regular cholesterol testing include family history of heart disease; individuals with high blood pressure, diabetes, and obesity; all regarded to be high risk factors. Tests for cholesterol include Complete Lipid Profile / Lipid Panel Test (providing Total Cholesterol, LDL cholesterol, HDL cholesterol, and Triglycerides levels); Apolipoprotein B Test; Apolipoprotein A1 and other tests. Growth in the cholesterol testing market is encouraged by growing awareness over the importance of testing as a measure to reduce fatality and improve diagnosis and treatment of CVD.
Other key factors driving growth in the market include improved understanding of CVD, development of biomarkers to effectively identify the risk of the condition, and increase in healthcare spending. Rising preference for CVD risk assessment owing to reduced insurance coverage and increasing out-of-pocket expenses associated with therapeutic treatments, is additionally promoting preventive healthcare practices. A vast majority of population remains undiagnosed thus promising significant opportunities for growth of testing volumes. New guidelines, publications, and awareness programs will additionally boost testing volumes. Rising preference for healthy lifestyles and improved quality of life among individuals is a key factor driving demand for cholesterol and other cardiovascular risk assessment tests.
Lipid Panel Test/Complete Lipid Profile is the most prevalent and widely recommended cholesterol test type globally. However, new variants of cardiovascular and other tests such as homocysteine test, C-reactive protein test are growing in popularity, promising more accuracy in CVD risk assessment. Technological advancements resulting in miniaturization of devices is expected to play a crucial role in driving demand for cholesterol self-test kits. Increasing preference for home testing and subsequent rise in demand for OTC cholesterol test kits is a key trend in the market.
As stated by the new market research report on Cholesterol Testing, Asia-Pacific ranks as the fastest growing market worldwide. Favorable demographical factors such as the rising population, better access to affordable healthcare, changing lifestyles and the subsequent rise in risk of cardiovascular diseases, are major factors promoting growth in the region. China is forecast to grow at a CAGR of 7.5% over the analysis period, led by rising disposable income, growing health consciousness, aging population, and growing awareness over available cholesterol testing solutions. The United States represents the largest market with cardiovascular diseases accounting for a major portion of dollars spent on chronic diseases in the country.
Key players covered in the report include Abbott Diagnostics Inc., AccuTech LLC, Alere Inc., Beckman Coulter Inc., Chek Diagnostics, F. Hoffmann-La Roche Ltd., Home Access Health Corporation, and Siemens Healthcare, among others.
The research report titled "Cholesterol Testing: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in dollars for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World. Test Types analyzed in the report include Lipid Panel Test/Complete Lipid Profile, Apolipoprotein B Test, and Other Cholesterol Tests.
Comments
Post a Comment